Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$51 Mln
P/E Ratio
--
P/B Ratio
10.31
Industry P/E
--
Debt to Equity
0
ROE
-1.56 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
A$-117.31 Mln
EBITDA
A$-119.26 Mln
Net Profit
A$-107.11 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Alterity Therapeutics - ADR
| 6.34 | -6.63 | 7.32 | 65.26 | -22.80 | -14.04 | -25.54 |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Alterity Therapeutics - ADR
| 32.62 | -28.49 | -51.39 | -46.27 | 71.79 | -39.06 | -58.77 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is... ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia. Address: 350 Collins Street, Melbourne, VIC, Australia, 3000 Read more
Co-Founder & Non-Executive Chairman
Mr. Geoffrey Paul Kempler B.Sc.
Co-Founder & Non-Executive Chairman
Mr. Geoffrey Paul Kempler B.Sc.
Headquarters
Melbourne, VIC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Alterity Therapeutics Limited - ADR stood at $ 21 Mln as on 31-Dec-24
The share price of Alterity Therapeutics Limited - ADR is $3.52 (NASDAQ) as of 23-Apr-2025 14:41 EDT. Alterity Therapeutics Limited - ADR has given a return of -22.8% in the last 3 years.
Alterity Therapeutics Limited - ADR has a market capitalisation of $ 51 Mln as on 22-Apr-2025. As per Value Research classification, it is a company.
The P/B ratio of Alterity Therapeutics Limited - ADR is 10.31 times as on 22-Apr-2025, a 348% premium to its peers’ median range of 2.30 times.
Since, TTM earnings of Alterity Therapeutics Limited - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Alterity Therapeutics Limited - ADR and enter the required number of quantities and click on buy to purchase the shares of Alterity Therapeutics Limited - ADR.
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia. Address: 350 Collins Street, Melbourne, VIC, Australia, 3000
The CEO & director of Mr. Geoffrey Paul Kempler B.Sc.. is Alterity Therapeutics Limited - ADR, and CFO & Sr. VP is Mr. Geoffrey Paul Kempler B.Sc..
There is no promoter pledging in Alterity Therapeutics Limited - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Alterity Therapeutics Limited - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-241.82
|
|
Operating margin(%)
|
-600.44
|
|
Net Margin(%)
|
-545.55
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Alterity Therapeutics Limited - ADR was $0 Mln.
$0.05
(
